DK0808367T3 - Vaskulære slimhindeaddressiner samt anvendelse deraf - Google Patents
Vaskulære slimhindeaddressiner samt anvendelse derafInfo
- Publication number
- DK0808367T3 DK0808367T3 DK96906504T DK96906504T DK0808367T3 DK 0808367 T3 DK0808367 T3 DK 0808367T3 DK 96906504 T DK96906504 T DK 96906504T DK 96906504 T DK96906504 T DK 96906504T DK 0808367 T3 DK0808367 T3 DK 0808367T3
- Authority
- DK
- Denmark
- Prior art keywords
- madcam
- primate
- recombinant
- proteins
- relates
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title 1
- 241000288906 Primates Species 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 210000000265 leukocyte Anatomy 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/386,857 US6551593B1 (en) | 1995-02-10 | 1995-02-10 | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US08/523,004 US7750137B2 (en) | 1995-09-01 | 1995-09-01 | Mucosal vascular addressins |
| PCT/US1996/002153 WO1996024673A1 (en) | 1995-02-10 | 1996-02-12 | Mucosal vascular addressins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0808367T3 true DK0808367T3 (da) | 2007-11-05 |
Family
ID=27011628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96906504T DK0808367T3 (da) | 1995-02-10 | 1996-02-12 | Vaskulære slimhindeaddressiner samt anvendelse deraf |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0808367B1 (es) |
| JP (1) | JP4205162B2 (es) |
| AT (1) | ATE366809T1 (es) |
| AU (1) | AU4986296A (es) |
| CA (1) | CA2212702C (es) |
| DE (1) | DE69637155T2 (es) |
| DK (1) | DK0808367T3 (es) |
| ES (1) | ES2290955T3 (es) |
| MX (1) | MX9706049A (es) |
| NZ (1) | NZ303523A (es) |
| PT (1) | PT808367E (es) |
| WO (1) | WO1996024673A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998020110A1 (en) * | 1996-11-01 | 1998-05-14 | Human Genome Sciences, Inc. | HUMAN MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MAdCAM-1) AND SPLICE VARIANTS THEREOF |
| WO1998051345A2 (en) * | 1997-05-09 | 1998-11-19 | The John P. Robarts Research Institute | Method for dislodging infiltrated leukocytes from a tissue |
| AU2007201698B2 (en) * | 1998-05-13 | 2011-10-13 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| JP4817494B2 (ja) * | 1998-05-13 | 2011-11-16 | ジェネンテック， インコーポレイテッド | 肝疾患の診断及び治療 |
| US7090845B2 (en) | 1998-05-13 | 2006-08-15 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| AUPR524101A0 (en) | 2001-05-25 | 2001-06-21 | Council Of The Queensland Institute Of Medical Research, The | Antigen targeting |
| AU2002351194A1 (en) * | 2001-11-30 | 2003-06-17 | Incyte Genomics, Inc. | Cell adhesion and extracellular matrix proteins |
| WO2004081049A1 (en) * | 2003-03-10 | 2004-09-23 | Auckland Uniservices Limited | Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof |
| PL1635855T3 (pl) | 2003-05-01 | 2011-04-29 | Scripps Research Inst | Selektywni antagoniści R-kadheryny i związane z nimi sposoby |
| UY28716A1 (es) * | 2004-01-09 | 2005-08-31 | Pfizer | Anticuerpos contra madcam |
| ES2911482T3 (es) * | 2004-09-03 | 2022-05-19 | Genentech Inc | Antagonistas anti-beta7 humanizados y usos para los mismos |
| ATE483732T1 (de) * | 2005-07-08 | 2010-10-15 | Pfizer Ltd | Madcam-antikörper |
| WO2007007152A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| KR101511453B1 (ko) * | 2008-05-16 | 2015-04-10 | 제넨테크, 인크. | 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| TWI698254B (zh) | 2011-05-02 | 2020-07-11 | 美商千禧製藥公司 | 抗-α4β7抗體之調配物 |
| EP3224280A1 (en) | 2014-11-26 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| WO2016105572A1 (en) | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| MA43755A (fr) | 2016-03-14 | 2018-11-28 | Millennium Pharm Inc | Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte |
| AU2017234009B2 (en) | 2016-03-14 | 2024-06-06 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| JP7162533B2 (ja) | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| WO2017218434A1 (en) | 2016-06-12 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| WO2018200818A2 (en) | 2017-04-28 | 2018-11-01 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders |
| MA48241A1 (fr) | 2017-07-14 | 2021-03-31 | Pfizer | Anticorps dirigés contre madcam |
| EP3972992A4 (en) * | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| WO2024252368A2 (en) | 2023-06-09 | 2024-12-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for treating ulcerative colitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013312A1 (en) * | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
-
1996
- 1996-02-12 EP EP96906504A patent/EP0808367B1/en not_active Revoked
- 1996-02-12 ES ES96906504T patent/ES2290955T3/es not_active Expired - Lifetime
- 1996-02-12 JP JP52449196A patent/JP4205162B2/ja not_active Expired - Fee Related
- 1996-02-12 NZ NZ303523A patent/NZ303523A/en not_active IP Right Cessation
- 1996-02-12 DK DK96906504T patent/DK0808367T3/da active
- 1996-02-12 AT AT96906504T patent/ATE366809T1/de active
- 1996-02-12 AU AU49862/96A patent/AU4986296A/en not_active Abandoned
- 1996-02-12 CA CA2212702A patent/CA2212702C/en not_active Expired - Lifetime
- 1996-02-12 MX MX9706049A patent/MX9706049A/es active IP Right Grant
- 1996-02-12 PT PT96906504T patent/PT808367E/pt unknown
- 1996-02-12 WO PCT/US1996/002153 patent/WO1996024673A1/en active IP Right Grant
- 1996-02-12 DE DE69637155T patent/DE69637155T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2212702C (en) | 2010-04-20 |
| PT808367E (pt) | 2007-10-22 |
| DE69637155T2 (de) | 2008-02-07 |
| ES2290955T3 (es) | 2008-02-16 |
| ATE366809T1 (de) | 2007-08-15 |
| JPH10513365A (ja) | 1998-12-22 |
| AU4986296A (en) | 1996-08-27 |
| NZ303523A (en) | 2002-02-01 |
| EP0808367B1 (en) | 2007-07-11 |
| WO1996024673A1 (en) | 1996-08-15 |
| CA2212702A1 (en) | 1996-08-15 |
| JP4205162B2 (ja) | 2009-01-07 |
| MX9706049A (es) | 1998-02-28 |
| EP0808367A1 (en) | 1997-11-26 |
| DE69637155D1 (de) | 2007-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0808367T3 (da) | Vaskulære slimhindeaddressiner samt anvendelse deraf | |
| Geiser et al. | The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes | |
| Pearse | Receptors compete for adaptors found in plasma membrane coated pits. | |
| Postlethwaite et al. | Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment. | |
| RU2734169C2 (ru) | Способ получения повышающей регуляции экспрессии PD-L1, полипептиды, конъюгат, слитый полипептид, композиция и комбинация для обеспечения повышающей регуляции экспрессии PD-L1 | |
| Timpl et al. | [47] Laminin | |
| DE60219611T2 (de) | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose | |
| KR100451446B1 (ko) | 아글리코 생성물 및 그의 사용 방법 | |
| JP2742925B2 (ja) | 血栓形成抑制用治療薬組成物 | |
| EP1581556A2 (en) | Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) | |
| JP2512453B2 (ja) | 天然のコロニ−促進因子―１の精製 | |
| JP2008101026A (ja) | 殺菌性／透過性が向上したタンパク質の機能領域に由来する生物学的に活性なペプチドおよびその使用 | |
| JP2004043502A (ja) | 新規蛋白質及びこれを使用した薬剤の製法 | |
| EP1399476B1 (de) | Verwendung löslicher cytokeratin-1-fragmente in diagnostik | |
| JPH03204896A (ja) | インターフェロンレセプター細胞外断片 | |
| JP4794102B2 (ja) | フィブリンのシトルリン誘導体及び慢性関節リウマチの診断又は治療のためのその使用 | |
| EP1683866B1 (en) | Deletion forms of IgE-dependent histamine releasing factor having histamine-releasing activity, HRF-binding peptides and the uses thereof | |
| AU6942994A (en) | Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof | |
| HU226468B1 (en) | Amino-terminally truncated mcp-2-as chemokine antagonists | |
| McNaughton et al. | Novel anti-inflammatory peptides based on chemokine–glycosaminoglycan interactions reduce leukocyte migration and disease severity in a model of rheumatoid arthritis | |
| EA009414B1 (ru) | Терапевтические применения вариантов хемокинов | |
| Campistol et al. | Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis | |
| Bond et al. | Native and recombinant Fel dI as probes into the relationship of allergen structure to human IgE immunoreactivity | |
| CN111848780A (zh) | 一种IL-36的可溶性受体sIL-36R及其应用 | |
| EP0698666B1 (en) | Modified epimorphin |